Matthew P. Coghlan
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Metabolism, Diabetes, and Cancer, Receptor Mechanisms and Signaling, Diabetes and associated disorders
Most-Cited Works
- → Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription(2000)888 cited
- → Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist(2020)445 cited
- → How May GIP Enhance the Therapeutic Efficacy of GLP-1?(2020)375 cited
- → Robust anti‐obesity and metabolic effects of a dual GLP ‐1/glucagon receptor peptide agonist in rodents and non‐human primates(2016)234 cited
- → Inhibition of GSK-3 Selectively Reduces Glucose-6-Phosphatase and Phosphoenolpyruvate Carboxykinase Gene Expression(2001)217 cited
- → GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice(2021)209 cited
- → c-Jun Is a JNK-independent Coactivator of the PU.1 Transcription Factor(1999)178 cited
- → Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist(2020)176 cited
- → Stimulation of Hepatocyte Glucose Metabolism by Novel Small Molecule Glucokinase Activators(2004)130 cited
- → Glucokinase activators in diabetes management(2008)112 cited